摘要
目的 观察肾康注射液联合百令胶囊治疗急性期COPD并发肾损害的临床效果.方法 2008～2011年,选择我科（呼吸,肾内）COPD合并肾损害（蛋白尿和/或急性肾衰竭）50例患者为研究对象,随机分为二组：常规治疗组、肾康治疗组,每组25例,分别在治疗时及治疗后2周、4周检查24h尿清蛋白,血尿素氮,血肌酐、FEV1%和全血粘度等指标,并观察其变化.结果 ①在治疗2周后,常规治疗组尿清蛋白、血尿素氮、血肌酐、FEV1%和全血粘度无明显改变（P〉0.05）;肾康组与治疗前比较差异有统计学意（P〈0.05）.②4周后,常规组24h尿清蛋白,血尿素氮,血肌酐与治疗前相比较差异有统计学意义（P〈0.05）,但FEV1%和全血粘度无变化;肾康组除FEV1%明显上升外,其余指标均进一步下降 （P〈0.01）.结论肾康注射液联合百令胶囊治疗急性加重期COPD并发肾损害有良好的治疗效果。
Objective To observe the clinical effect of shenkang injection and corbrin capsule on kidney injury by COPD（ acute period）. Methods Fifty COPD cases,who have kidney injury（acute renal failure） were randomly divided into shenkang group and control group,each group has 25 patients. BUN,Scr FEVI% and of 50 cases weredetected and compared be- fore treatment and after therapy 2weeks,,4weeks. Results After therapy 2weeks, BUN,Scr,FEV1% of control group has not sig- nificantly changed（ P 〉 0.05 ）, butshenkang group has obviously different（ P 〈 0. 05 ）, compared with before treatment. After treat- ment 4weeks, BUN, Scr, was decreased （ P 〈 0. 05 ）, while FEV1%, still retain stable （ P 〉 O. 05 ） in control; at the same time, BUN,Scr was greater reduction （P 〈 0. 01 ）, but FEV1% increased（ P 〈 0. 01 ） in shenkang group, compared with before therapy. Conclusion Shenkang injection and corbrin capsule hasd significant effect on kidney injury by COPD, and more, they can improve of who have COPD.
出处
《四川医学》
CAS
2013年第11期1683-1685,共3页
Sichuan Medical Journal
